Anavex raises $1.575 million
Sources News Release
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 11/07/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73 the companys lead drug candidate
Abstract: Hoboken, NJ July 11, 2011 -- Anavex Life Sciences Corp. (Anavex) (OTCBB: AVXL) is pleased to announce that it has raised $1,575,000 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the companys lead drug candidate for Alzheimers disease, to advance other compounds in the Anavex pipeline, and for general corporate purposes.
"Anavex appreciates the continued support of its shareholders. The warrant exercise was an ideal way for u...
To read the full release go to http://www.sources.com/Releases/NR1363.htm
© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.